Milestones in research on the pathophysiology of Parkinson's disease

Movement Disorders

Volumn 26, Issue 6, 2011, Pages 1032-1041

  Wichmann, Thomas ^a,b   Delong, Mahlon R ^a   Guridi, Jorge ^c,d   Obeso, Jose A ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Basal ganglia; Deep brain stimulation; Direct pathway; Dyskinesias; Indirect pathway; Pallidotomy

Indexed keywords

ABLATION THERAPY; AKINESIA; BASAL GANGLION; BRADYKINESIA; BRAIN DEPTH STIMULATION; CELL SYNCHRONIZATION; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; HUMAN; NERVE CELL; NONHUMAN; OSCILLATORY POTENTIAL; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBTHALAMIC NUCLEUS; TREMOR;

ANIMALS; BASAL GANGLIA; BIOMEDICAL RESEARCH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE;

EID: 79957606507     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23695     Document Type: Review

References (115)

1. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249(Suppl 3): III/1-5.
2. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008; 64: 485-491.
3. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61: 413-426.
4. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010; 25(Suppl 1): S78-S82.
5. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 79-84.
6. Jellinger KA. Critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2010; 67: 550.
7. DeLong MR, Georgopoulos AP. Motor functions of the basal ganglia. In: Brookhart JM, Mountcastle VB, Brooks VB, Geiger SR, eds. Handbook of Physiology The Nervous System Motor Control. Section 1, Vol. II, Part 2. Bethesda, MD: American Physiological Society; 1981: 1017-1061.
8. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
9. Kelly RM, Strick PL. Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog Brain Res 2004; 143: 449-459.
10. Bergman H, Feingold A, Nini A, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 1998; 21: 32-38.
11. Turner RS, Grafton ST, Votaw JR, Delong MR, Hoffman JM. Motor subcircuits mediating the control of movement velocity: a PET study. J Neurophysiol 1998; 80: 2162-2176.
12. Hoover JE, Strick PL. Multiple output channels in the basal ganglia. Science 1993; 259: 819-821.
13. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Rev 2000; 31: 236-250.
14. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. KlinWschr 1960; 38: 1236-1239.
15. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain. dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415-455.
16. Penney JBJr., Young AB. Striatal inhomogeneities and basal ganglia function. Mov Disord 1986; 1: 3-15.
17. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375.
18. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-285.
19. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432.
20. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1438.
21. Hartmann-von Monakow K, Akert K, Kunzle H. Projections of the precentral motor cortex and other cortical areas of the frontal lobe to the subthalamic nucleus in the monkey. Exp Brain Res 1978; 33: 395-403.
22. Nambu A, Tokuno H, Hamada I, et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 2000; 84: 289-300.
23. Tokuno H, Nambu A. Organization of nonprimary motor cortical inputs on pyramidal and nonpyramidal tract neurons of primary motor cortex: An electrophysiological study in the macaque monkey. Cerebr Cortex 2000; 10: 58-68.
24. Gertler TS, Chan CS, Surmeier DJ. Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 2008; 28: 10814-10824.
25. Taverna S, Ilijic E, Surmeier DJ. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci 2008; 28: 5504-5512.
26. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007; 445: 643-647.
27. Day M, Wokosin D, Plotkin JL, Tian X, Surmeier DJ. Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci 2008; 28: 11603-11614.
28. Bateup HS, Santini E, Shen W, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A 2010; 107: 14845-14850.
29. Tian X, Kai L, Hockberger PE, Wokosin DL, Surmeier DJ. MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. Mol Cell Neurosci 2010; 44: 94-108.
30. Kravitz AV, Freeze BS, Parker PR, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010; 466: 622-626.
31. Birkmayer W, Hornykiewicz O. Der L-3dioxphenylalanin (DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961; 73: 787-788.
32. Carlsson A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl, 1972; 51: 11-42.
33. Yahr MD, Duvoisin RC. Drug therapy of parkinsonism. N Engl J Med 1972; 287: 20-24.
34. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1: 249-254.
35. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
36. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80: 4546-4550.
37. Crossman AR, Mitchell IJ, Sambrook MA. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology 1985; 24: 587-591.
38. Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. Neural mechanisms mediating 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Lett 1986; 63: 61-65.
39. Schwartzman RJ, Alexander GM. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. Brain Res 1985; 358: 137-143.
40. Schwartzman RJ, Alexander GM. Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease. Adv Neurol 1987; 45: 171-173.
41. Miller WC, DeLong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A, eds. The Basal Ganglia II. New York: Plenum Press; 1987: 415-427.
42. Filion M, Tremblay L, Bedard PJ. Excessive and Unselective Responses of Medial Pallidal Neurons to Both Passive Movements and Striatal Stitmulation in Monkeys with MPTP-Induced Parkinsonism. London: John Libbey; 1989.
43. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991; 547: 142-151.
44. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990; 5: 100-108.
45. Mitchell IJ, Sambrook MA, Crossman AR. Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain 1985; 108: 405-422.
46. Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res 1985; 339: 346-350.
47. Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. Brain 1988; 111: 1211-1233.
48. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding. J Neurophysiol 1992; 68: 1859-1866.
49. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 1992; 68: 1850-1858.
50. Obeso JA, Rodriguez MC, DeLong MR. Basal ganglia pathophysiology. A critical review. Adv Neurol 1997; 74: 3-18.
51. Ceballos-Bauman AO, Obeso JA, Vitek JL, et al. Restoration of thalamocortical activity after posteroventrolateral pallidotomy in Parkinson's disease. Lancet 1994; 344: 814.
52. Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 1994; 72: 521-530.
53. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991; 6: 288-292.
54. Guridi J, Herrero MT, Luquin MR, et al. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996; 119: 1717-1727.
55. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61.
56. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40: 355-366.
57. Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 1997; 350: 1224.
58. Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord 2001; 16: 72-78.
59. Alvarez L, Macias R, Lopez G, et al. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. Brain 2005; 128: 570-583.
60. Alvarez L, Macias R, Pavon N, et al. Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry 2009; 80: 979-985.
61. Benabid AL, Pollak P, Louveau A, Henry S, Rougemont Jd. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987; 50: 344-346.
62. Benabid AL, Pollak P, Gervason C, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403-406.
63. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993; 5: 382-389.
64. Limousin P, Pollak P, Benazzouz A, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995; 10: 672-674.
65. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128: 2240-2249.
66. Rodriguez-Oroz MC, Gorospe A, Guridi J, et al. Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology 2000; 55: S45-S51.
67. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63-73.
68. Brown P, Eusebio A. Paradoxes of functional neurosurgery: clues from basal ganglia recordings. Mov Disord 2008; 23: 12-20; quiz 158.
69. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-24.
70. Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 1994; 117: 877-897.
71. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994; 72: 507-520.
72. Wichmann T, Soares J. Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol 2006; 95: 2120-2133.
73. Bevan MD, Wilson CJ, Bolam JP, Magill PJ. Equilibrium potential of GABA(A) current and implications for rebound burst firing in rat subthalamic neurons in vitro. J Neurophysiol 2000; 83: 3169-3172.
74. Hallworth NE, Bevan MD. Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors. J Neurosci 2005; 25: 6304-6315.
75. Bevan MD, Hallworth NE, Baufreton J. GABAergic control of the subthalamic nucleus. Prog Brain Res 2007; 160: 173-188.
76. Nambu A, Llinas R. Electrophysiology of globus pallidus neurons in vitro. J Neurophysiol 1994; 72: 1127-1139.
77. Cooper AJ, Stanford IM. Electrophysiological and morphological characteristics of three subtypes of rat globus pallidus neurone in vitro. J Physiol 2000; 527: 291-304.
78. Levy R, Hutchison WD, Lozano AM, Dostrovsky JO. High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor. J Neurosci 2000; 20: 7766-7775.
79. Goldberg JA, Boraud T, Maraton S, Haber SN, Vaadia E, Bergman H. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine primate model of Parkinson's disease. J Neurosci 2002; 22: 4639-4653.
80. Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 2006; 52: 155-168.
81. Raz A, Feingold A, Zelanskaya V, Vaadia E, Bergman H. Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol 1996; 76: 2083-2088.
82. Raz A, Vaadia E, Bergman H. Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine vervet model of parkinsonism. J Neurosci 2000; 20: 8559-8571.
83. Cassidy M, Mazzone P, Oliviero A, et al. Movement-related changes in synchronization in the human basal ganglia. Brain 2002; 125: 1235-1246.
84. Hammond C, Bergman H, Brown P. Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci 2007; 30: 357-364.
85. Gatev P, Darbin O, Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 2006; 21: 1566-1577.
86. Rivlin-Etzion M, Marmor O, Heimer G, Raz A, Nini A, Bergman H. Basal ganglia oscillations and pathophysiology of movement disorders. Curr Opin Neurobiol 2006; 16: 629-637.
87. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 2001; 21: 1033-1038.
88. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 2003; 18: 357-363.
89. Brown P. Abnormal oscillatory synchronisation in the motor system leads to impaired movement. Curr Opin Neurobiol 2007; 17: 656-664.
90. Alonso-Frech F, Zamarbide I, Alegre M, et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain 2006; 129: 1748-1757.
91. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2010.
92. Leblois A, Meissner W, Bioulac B, Gross CE, Hansel D, Boraud T. Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. Eur J Neurosci 2007; 26: 1701-1713.
93. Mallet N, Pogosyan A, Sharott A, et al. Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci 2008; 28: 4795-4806.
94. Chevalier G, Deniau JM. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 1990; 13: 277-280.
95. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-271.
96. Mink JW, Thach WT. Basal ganglia intrinsic circuits and their role in behavior. Curr Opin Neurobiol 1993; 3: 950-957.
97. Nambu A. Seven problems on the basal ganglia. Curr Opin Neurobiol 2008; 18: 595-604.
98. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 2002; 43: 111-117.
99. Boraud T, Bezard E, Bioulac B, Gross CE. Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. J Neurophysiol 2000; 83: 1760-1763.
100. Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 2010; 11: 760-772.
101. Merello M, Balej J, Tenca E, Leiguarda R. Kinematic evaluation of gestural and repetitive single joint movements of the arm after posteroventral pallidotomy, subthalamotomy or both procedures combined in two Parkinson's disease patients: two case studies. Eur J Neurol 2008; 15: 406-412.
102. Obeso JA, Jahanshahi M, Alvarez L, et al. What can man do without basal ganglia motor output? The effect of combined unilateral subthalamotomy and pallidotomy in a patient with Parkinson's disease. Exp Neurol 2009; 220: 283-292.
103. Villalba RM, Lee H, Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol 2009; 215: 220-227.
104. Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 1989; 503: 334-338.
105. Ingham CA, Hood SH, Taggart P, Arbuthnott GW. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J Neurosci 1998; 18: 4732-4743.
106. Ingham CA, Hood SH, van Maldegem B, Weenink A, Arbuthnott GW. Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp Brain Res 1993; 93: 17-27.
107. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005; 132: 741-754.
108. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 2006; 9: 251-259.
109. Wang Z, Kai L, Day M, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006; 50: 443-452.
110. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 2000; 47: 345-352.
111. Aymerich MS, Barroso-Chinea P, Perez-Manso M, et al. Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. Eur J Neurosci 2006; 23: 2099-2108.
112. Rommelfanger KS, Wichmann T. Extranigrostriatal dopaminergic circuits of the basal ganglia. Front Neuroanat 2010; 4: 139.
113. Pifl C, Bertel O. G. S, Hornykiewicz O. Extrastriatal dopamine in symptomatic and asymptomatic Rhesus monkeys treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Neurochem Int 1990; 17: 263-270.
114. Knowlton BJ, Mangels JA, Squire LR. A neostriatal habit learning system in humans. Science 1996; 273: 1399-1402.
115. Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol 2008; 119: 1459-1474.